Boehringer beats Bayer to the regulators
The FDA will rule on a low dose of zongertinib in the summer.
FDA red and green lights: January 2025
AstraZeneca bags three of the month’s four oncology approvals.
Vir shows up Sanofi
Two masked bispecific antibodies, licensed for $100m, produce promising early data.
